康柏西普联合激光治疗视网膜静脉血管阻塞并发黄斑囊样水肿疗效观察
|
摘要
目的探讨康柏西普联合激光治疗视网膜静脉血管阻塞并发黄斑囊样水肿的疗效。方法选取医院2017年1月至2018年1月收治的视网膜静脉血管阻塞并发黄斑囊样水肿患者75例,依据治疗方法不同分为两组,对照组(36例)予以激光治疗,试验组(39例)予以康柏西普联合激光治疗。比较两组患者的黄斑中心视网膜厚度(CMT)、最佳视力矫正(BCVA)、眼底荧光造影(FFA)。结果治疗后,试验组患者的CMT及BCVA均优于对照组,FFA渗漏率低于对照组(P <0. 05);试验组并发症发生率为2. 56%,显著低于对照组的16. 67%(P <0. 05)。结论康柏西普联合激光治疗视网膜静脉血管阻塞样并发黄斑囊样水肿,可有效改善CMT和BCVA,减少渗漏及并发症,值得临床推广。
Objective To investigate conbercept combined with the laser in the treatment of retinal vein occlusion( RVO) complicated with cystoid macular edema( CME). Methods Totally 75 patients with RVO complicated with CME admitted to our hospital from January 2017 to January 2018 were selected and divided into two groups according to the different treatment methods. The patients( 36 cases) in the control group were treated with laser,while the patients( 39 cases) in the experimental group were treated with laser combined with conbercept. The central macular thickness( CMT),best corrected visual acuity( BCVA) and fluorescein fundus angiography( FFA) were compared between the two groups. Results After treatment,the CMT and BCVA of the experimental group were better than those of the control group,and the leakage rate of FFA in the experimental group was lower than that in the control group( P < 0. 05).he incidence rate of complications in the experimental group was 2. 56%, which was significantly lower than 16. 67% of the control group( P < 0. 05). Conclusion Conbercept combined with the laser in the treatment of RVO complicated with CME can effectively improve CMT and BCVA,reduce the incidence of leakage and complications,which is worthy of clinical promotion.
Objective To investigate conbercept combined with the laser in the treatment of retinal vein occlusion( RVO) complicated with cystoid macular edema( CME). Methods Totally 75 patients with RVO complicated with CME admitted to our hospital from January 2017 to January 2018 were selected and divided into two groups according to the different treatment methods. The patients( 36 cases) in the control group were treated with laser,while the patients( 39 cases) in the experimental group were treated with laser combined with conbercept. The central macular thickness( CMT),best corrected visual acuity( BCVA) and fluorescein fundus angiography( FFA) were compared between the two groups. Results After treatment,the CMT and BCVA of the experimental group were better than those of the control group,and the leakage rate of FFA in the experimental group was lower than that in the control group( P < 0. 05).he incidence rate of complications in the experimental group was 2. 56%, which was significantly lower than 16. 67% of the control group( P < 0. 05). Conclusion Conbercept combined with the laser in the treatment of RVO complicated with CME can effectively improve CMT and BCVA,reduce the incidence of leakage and complications,which is worthy of clinical promotion.
引文
[1]韩克阳,王淑雅,焦芮,等.视网膜静脉阻塞的发病机制及黄斑水肿的抗-VEGF治疗[J].山东大学耳鼻喉眼学报,2017,31(1):123-126.
[2]沈丽君,吴素兰.视网膜分支静脉阻塞以及继发黄斑水肿治疗现状困惑与思考[J].中华眼底病杂志,2017,33(2):114-118.
[3] PAPAKOSTAS TD,LIM L,ZYL TV,et al. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab[J].Eye,2016,33(1):635-636.
[4]王文玲,户秀慧. FFA和OCT在诊断视网膜中央动静脉阻塞中的应用价值[J].国际眼科杂志,2016,16(10):1946-1948.
[5]龙盘,吴一冰,赵健,等.视网膜静脉阻塞药物治疗方法和进展[J].国际眼科杂志,2017,17(11):2055-2059.
[6]张敏,朱健华,冯浩,等.视网膜静脉阻塞合并黄斑水肿患者黄斑区微结构改变与视力的相关性分析[J].眼科新进展,2016,36(11):1061-1064.
[7] BALARATNASINGAM C,INOUE M,AHN S,et al. Visual Acuity Is Correlated with the Area of the Foveal Avascular Zone in Diabetic Retinopathy and Retinal Vein Occlusion[J]. Ophthalmology,2016,123(11):2352-2367.
[8]张燕,蔡岩,张小玲,等.激光致黄斑损伤的临床分析[J].国际眼科杂志,2016,16(6):1176-1179.
[9]杨红霞,高钰昆,王卓伟,等.后Tenon囊注射曲安奈德联合格栅样光凝治疗视网膜中央静脉阻塞黄斑水肿激光时机的选择[J].中国药物与临床,2017,17(9):1375-1377.
[10]朱平利,徐玲,安良宝,等.玻璃体腔内注射康桕西普治疗黄斑部小分支视网膜静脉阻塞导致的黄斑水肿[J].国际眼科杂志,2018,18(1):159-162.
[11] YOUNG KZ,DEDANIA VS,RAO RC. Acute-on-Chronic:Retinal Artery Occlusion Following Retinal Vein Occlusion[J].Ophthalmology,2017,124(8):1142.
[12]赵洁文,李明新.玻璃体腔注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的疗效观察[J].中国眼耳鼻喉科杂志,2018,18(1):26-28.
[13]毛剑波,褚梦琪,陈亦棋,等.玻璃体腔注射康柏西普治疗视网膜静脉阻塞黄斑水肿短期疗效观察[J].中华眼底病杂志,2016,32(4):372-376.
[14]马锋伟,杜翠云,程美红,等.康柏西普与曲安奈德玻璃体腔注射治疗视网膜中央静脉阻塞继发黄斑水肿临床疗效的比较[J].中华实验眼科杂志,2016,34(9):837-841.
[2]沈丽君,吴素兰.视网膜分支静脉阻塞以及继发黄斑水肿治疗现状困惑与思考[J].中华眼底病杂志,2017,33(2):114-118.
[3] PAPAKOSTAS TD,LIM L,ZYL TV,et al. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab[J].Eye,2016,33(1):635-636.
[4]王文玲,户秀慧. FFA和OCT在诊断视网膜中央动静脉阻塞中的应用价值[J].国际眼科杂志,2016,16(10):1946-1948.
[5]龙盘,吴一冰,赵健,等.视网膜静脉阻塞药物治疗方法和进展[J].国际眼科杂志,2017,17(11):2055-2059.
[6]张敏,朱健华,冯浩,等.视网膜静脉阻塞合并黄斑水肿患者黄斑区微结构改变与视力的相关性分析[J].眼科新进展,2016,36(11):1061-1064.
[7] BALARATNASINGAM C,INOUE M,AHN S,et al. Visual Acuity Is Correlated with the Area of the Foveal Avascular Zone in Diabetic Retinopathy and Retinal Vein Occlusion[J]. Ophthalmology,2016,123(11):2352-2367.
[8]张燕,蔡岩,张小玲,等.激光致黄斑损伤的临床分析[J].国际眼科杂志,2016,16(6):1176-1179.
[9]杨红霞,高钰昆,王卓伟,等.后Tenon囊注射曲安奈德联合格栅样光凝治疗视网膜中央静脉阻塞黄斑水肿激光时机的选择[J].中国药物与临床,2017,17(9):1375-1377.
[10]朱平利,徐玲,安良宝,等.玻璃体腔内注射康桕西普治疗黄斑部小分支视网膜静脉阻塞导致的黄斑水肿[J].国际眼科杂志,2018,18(1):159-162.
[11] YOUNG KZ,DEDANIA VS,RAO RC. Acute-on-Chronic:Retinal Artery Occlusion Following Retinal Vein Occlusion[J].Ophthalmology,2017,124(8):1142.
[12]赵洁文,李明新.玻璃体腔注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的疗效观察[J].中国眼耳鼻喉科杂志,2018,18(1):26-28.
[13]毛剑波,褚梦琪,陈亦棋,等.玻璃体腔注射康柏西普治疗视网膜静脉阻塞黄斑水肿短期疗效观察[J].中华眼底病杂志,2016,32(4):372-376.
[14]马锋伟,杜翠云,程美红,等.康柏西普与曲安奈德玻璃体腔注射治疗视网膜中央静脉阻塞继发黄斑水肿临床疗效的比较[J].中华实验眼科杂志,2016,34(9):837-841.